Search results for "microRNA"

showing 10 items of 577 documents

73P microRNA expression profiles of single hormone receptor-positive breast cancers

2020

OncologyExpression (architecture)Hormone receptorbusiness.industrymicroRNACancer researchMedicineHematologybusinessAnnals of Oncology
researchProduct

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

2018

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysi…

OncologyHepatocellular carcinomalaw.inventionLeukocyte Count0302 clinical medicineRandomized controlled trialNeutrophil-tolymphocyte ratiolawMedicineNeutrophil-to-lymphocyte ratioLiver NeoplasmsGastroenterologyMicroRNAGeneral MedicineSorafenibPrognosisTreatment OutcomeLiver030220 oncology & carcinogenesisHepatocellular carcinomaBiomarker (medicine)030211 gastroenterology & hepatologyAdverse events; Angiopoietin; Biomarker; Hepatocellular carcinoma; MicroRNA; Neutrophil-tolymphocyte ratio; Polymorphisms; Sorafenib; Vascular endothelial growth factor; Gastroenterologymedicine.drugAdverse eventSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsSingle-nucleotide polymorphismAngiopoietin03 medical and health sciencesInternal medicineBiomarkers TumorHumansNeoplasm InvasivenessPolymorphismNeutrophil to lymphocyte ratioAdverse effectbusiness.industryBiomarkermedicine.diseasedigestive system diseasesClinical Trials Phase III as TopicDrug Resistance NeoplasmAdverse eventsEtiologyVascular endothelial growth factorbusinessPolymorphisms
researchProduct

A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types

2020

The purpose of this study is to clinically validate a series of circulating miRNAs that distinguish between the 4 most prevalent tumor types (lung cancer (LC)

OncologyMaleLung NeoplasmsColorectal cancerlcsh:ChemistryProstate cancer0302 clinical medicinelcsh:QH301-705.5SpectroscopyEarly Detection of CancerAged 80 and over0303 health sciencesArea under the curveGeneral MedicineMiddle AgedEarly diagnosisprostate cancer3. Good healthComputer Science Applications030220 oncology & carcinogenesisArea Under CurveFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyBreast Neoplasmscolorectal cancerCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineHumansCirculating MicroRNAPhysical and Theoretical ChemistryLung cancerMolecular Biology030304 developmental biologyAgedNeoplasm StagingReceiver operating characteristicbusiness.industryOrganic ChemistryCancerProstatic Neoplasmsmedicine.diseaseCirculating MicroRNAlung cancerlcsh:Biology (General)lcsh:QD1-999ROC CurveCase-Control StudiesMultivariate Analysiscirculating microRNAsbusinessInternational Journal of Molecular Sciences
researchProduct

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

2021

During a severe infection such as coronavirus disease 2019 (COVID-19), the level of almost all analytes can change, presenting a correlation with disease severity and survival; however, a biomarker cannot be translated into clinical practice for treatment guidance until it is proven to have a significant impact. Several studies have documented the association between COVID-19 severity and circulating levels of C-reactive protein (CRP) and interleukin-6, and the accuracy of the CRP level in predicting treatment responses has been evaluated. Moreover, promising findings on prothrombin and D-dimer have been reported. However, the clinical usefulness of these biomarkers in COVID-19 is far from …

OncologyTreatment responsemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Clinical BiochemistryPredictive valueReview Articlemacromolecular substances030204 cardiovascular system & hematologySeverity of Illness IndexSeverityGeneral Laboratory MedicineFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineDisease severityInternal medicineSeverity of illnessHumansMedicine030212 general & internal medicineInterleukin 6biologyInterleukin-6SARS-CoV-2business.industryBiochemistry (medical)C-reactive proteinCOVID-19General MedicinePrognosisCoronavirusClinical PracticeMicroRNAsC-Reactive Proteinbiology.proteinBiomarker (medicine)businessBiomarkersAnnals of Laboratory Medicine
researchProduct

Plasma circulating miRNAs as diagnostic and prognostic biomarkers in alpha-1 antitrypsin deficiency

2019

Introduction: Alpha-1 antitrypsin (AATD) deficiency is an inherited condition that leads to decreased circulating AAT levels, significantly increasing the risk of lung and liver disease. AATD is underdiagnosed. Severity of symptoms in AATD patients are highly variable and neither protein levels nor phenotype are sufficient to identify which patients will develop lung and/or liver disease. Therefore, new strategies and biomarkers for early diagnosis and prognosis of the disease are needed. Rationale and Aims: MicroRNAs (miRNAs) regulate gene expression and have been associated with the pathogenesis of various lung and liver diseases. Circulating miRNAs may serve as diagnostic and prognostic …

Oncologymedicine.medical_specialtyAlpha 1-antitrypsin deficiencyLungbusiness.industryDiseasemedicine.diseasePhenotypePathogenesisLiver diseasemedicine.anatomical_structureInternal medicinemicroRNAGene chip analysismedicinebusinessMolecular pathology and funct. genomics
researchProduct

Differential microRNA expression in breast cancer patients aged 35 years or younger

2015

Oncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicinemicroRNAmedicineCancerHematologymedicine.diseasebusinessAnnals of Oncology
researchProduct

Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer

2013

Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms of folate pathway genes for pemetrexed metabolism have not been fully elucidated yet. The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. miR-22, miR-24, …

Oncologymedicine.medical_specialtyChemotherapyPhysiologybusiness.industrymedicine.medical_treatmentClinical BiochemistryCellCell BiologyBioinformaticsmedicine.diseasemedicine.anatomical_structurePemetrexedInternal medicinemicroRNAmedicineClinical significancebusinessLung cancerProgressive diseaseWhole bloodmedicine.drugJournal of Cellular Physiology
researchProduct

Diagnostic and prognostic value of three micrornas in environmental asbestiform fibers-associated malignant mesothelioma

2021

Fluoro-edenite (FE) is an asbestiform fiber identified in Biancavilla (Sicily, Italy). Environmental exposure to FE has been associated with a higher incidence of malignant mesothelioma (MM). The present study aimed to validate the predicted diagnostic significance of hsa-miR-323a-3p, hsa-miR-101-3p, and hsa-miR-20b-5p on a subset of MM patients exposed to FE and matched with healthy controls. For this purpose, MM tissues vs. nonmalignant pleura tissues were analyzed through droplet digital PCR (ddPCR) to evaluate differences in the expression levels of the selected miRNAs and their MM diagnostic potential. In addition, further computational analysis has been performed to establish the corr…

Oncologymedicine.medical_specialtyFluoro-edenitediagnosisMedicine (miscellaneous)AsbestoAsbestiformmedicine.disease_causeAsbestosArticleInternal medicinemicroRNAmedicineDigital polymerase chain reactionMesotheliomaMalignant mesotheliomaReceiver operating characteristicbusiness.industryIncidence (epidemiology)RMicroRNAEnvironmental exposuremedicine.diseaseasbestosPrognosisMedicinebusinessDiagnosi
researchProduct

Early detection of lung cancer in exhaled breath condensate using miRNA markers

2015

Background: Lung cancer is the leading cause of death by cancer worldwide. Since 5-year survival rate increases significantly when lung cancer is diagnosed at early stages, the development of accurate non-invasive biomarkers for early lung cancer diagnosis is of utmost importance. Over the last years, several tumour biomarkers based on microRNAs (miRNAs) determined in exhaled breath condensate (EBC) have been evaluated and could be applied to early diagnosis of lung cancer. Rationale: miRNA signatures for surgical specimens of lung cancer have been determined providing a panel of differentially expressed miRNAs that were able to discriminate lung cancer patients from normal subjects. Using …

Oncologymedicine.medical_specialtybusiness.industryCancerEarly detectionDifferentially expressed mirnasrespiratory systemmedicine.diseaserespiratory tract diseasesInternal medicinemicroRNAMedicineExhaled breath condensatebusinessLung cancerSurvival rateCause of death11.1 Lung Cancer
researchProduct

Upregulated Mirna 21 in Kras Mutated Patients is Related to Prognosis in Resectable Non-Small Cell Lung Cancer

2015

Oncologymedicine.medical_specialtybusiness.industryHematologymedicine.diseasemedicine.disease_causeOncologyInternal medicineMutation (genetic algorithm)microRNAmedicineNon small cellKRASbusinessLung cancerAnnals of Oncology
researchProduct